The Danish pharmaceutical company Novo Nordisk announced Tuesday that it has implemented substantial price cuts for its widely-used medications Ozempic and Wegovy in the Indian market, reducing costs by up to 36% and 48% respectively.
The price reductions come as the company faces increasing competition from Indian pharmaceutical manufacturers who are introducing lower-cost generic versions of these diabetes and weight-loss treatments into the market.
This marks another round of price decreases for the popular medications as Novo Nordisk works to maintain its market position against the growing presence of more affordable alternatives produced by local Indian drugmakers.
